Paul Antony (born 1962) is a physician executive and former Chief Medical Officer for the Pharmaceutical Research and Manufacturers of America (PhRMA) http://www.phrma.org. He left PhRMA to serve as CEO of Callidus Biopharma until its acquisition by Amicus Therapeutics (NASDAQ: FOLD) http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=808736 .
Board-certified in both preventive medicine and aerospace medicine, he received his MD and MPH degrees from the George Washington University.[1] Prior to attending medical school, he earned an MBA from Harvard Business School and worked for McKinsey & Company, where he specialized in post-merger integration within the health care and high technology industries http://www.linkedin.com/in/paulantony.
Antony is a Commander in the United States Navy, Medical Corps. His last active-duty assignment was with the White House Military Office as Flight Surgeon and senior medical officer for the Marine One Presidential Helicopter Squadron. He continues to serve as a reserve officer and his military experience includes support of Naval Special Warfare and combat & humanitarian deployments to Afghanistan, Iraq, Haiti, & Guantanamo Bay, Cuba. Antony was a 1993-1994 White House Fellow serving in the Executive Office of the President http://www.whff.org/. He received his bachelor of science degree in biomedical engineering from Johns Hopkins Universityhttp://www.jhu.edu/ and spent five years developing new products for Hewlett-Packard and AT&T. He now serves as a Senior Fellow with FasterCures http://www.fastercures.org/about/staff-and-fellows/.